Articles From: Amgen to Pay $24.9 Million to Settle Kickbacks Allegations to Amira Nature Foods Ltd to Present at the UBS Global Consumer Conference


2013/4/16
Amgen Inc. (AMGN) will pay $24.9 million to settle allegations that it paid kickbacks to certain long-term care pharmacy providers, the Justice Department said.
Sign-up for Amgen to Pay $24.9 Million to Settle Kickbacks Allegations investment picks
2013/4/16
Amgen Inc. (AMGN) will pay $24.9 million to settle allegations that it paid kickbacks to certain long-term care pharmacy providers, the Justice Department said.
Sign-up for Amgen to Pay $24.9 Million to Settle U.S. Allegations of Kickbacks investment picks
2013/3/1
THOUSAND OAKS, Calif.
Sign-up for Amgen To Present At The Cowen and Company 33rd Annual Health Care Conference investment picks
2013/1/31
THOUSAND OAKS, Calif.
Sign-up for Amgen To Webcast 2013 Business Review Meeting On February 7 investment picks
2013/5/7
Amgen Inc. (AMGN) said a late-stage trial testing its colon cancer drug Vectibix showed it was competitive with a rival option from German pharmaceutical and chemical company Merck KGaA (MKGAY, MRK.XE). Amgen said the trial put the drug "head-to-head" with Merck KGaA's Erbitux, considered a standard colon cancer therapy along with Vectibix and Avastin, made by Roche Holding AG's (ROG.VX) Genentech unit.
Sign-up for Amgen Trial of Colon Cancer Drug Meets Goal investment picks
2013/4/23
First Quarter 2013 GAAP EPS Were $1.88 2013 Adjusted EPS Expected to be Above the Midpoint of the Range of $7.05-$7.35; 2013 Revenue Guidance Range of $17.8-$18.2 Billion Unchanged THOUSAND OAKS, Calif.
Sign-up for Amgen's First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96 investment picks
2013/3/26
– Worldwide Distribution Agreement Covers Key Medical Isotopes – KENNEWICK, Wash., March 26, 2013 (GLOBE NEWSWIRE) -- Advanced Medical Isotope Corporation ("AMIC") (OTCBB:ADMD) , a company engaged in the production and distribution of medical isotopes, has entered into a strategic alliance with GSG International GMbH to collaborate in the joint development of technologies for the production of medical isotopes and the marketing and distribution of related isotopes, equipment and services.
Sign-up for AMIC Enters Into Strategic Alliance With GSG International investment picks
2013/4/9
(TSX Symbol: ACC) – Amica Mature Lifestyles Inc. (“Amica” or the “Company”) is pleased to announce the Company’s operating and financial results for the third quarter, with several key items to highlight: “We are extremely pleased to report significant MARPAS growth of 6.8% for the three months and 6.9% for the nine months ended February 28, 2013, the highest growth we’ve seen since 2004,” said Samir Manji, Chairman, President and CEO of Amica Mature Lifestyles Inc. “Occupancy results increased across the board with overall occupancy in our mature communities growing by 3.7% to 94.5% at February 28, 2013, compared to February 29, 2012.
Sign-up for Amica Mature Lifestyles Announces Third Quarter Fiscal 2013 Results, Dividend, New Board of Director and Adoption of Advance Notice By-Laws investment picks
2013/3/7
(TSX Symbol: ACC) – Amica Mature Lifestyles Inc. (“Amica” or the “Company”) announced today that it will be releasing its third quarter results on Tuesday, April 9, 2013, after the market closes.
Sign-up for Amica Mature Lifestyles to Announce Third Quarter Fiscal 2013 Results and Host Conference Call April 10, 2013 investment picks
2013/2/14
Phase 2 AT2220-ERT Co-Administration and Preclinical AT2220-ERT Co-Formulation Studies Presented at LDN WORLD Symposium Next-Generation ERT Advancing in Preclinical Studies Conference Call on February 15, 2013 at 11:30am ET CRANBURY, N.J., and ORLANDO, Fla., Feb.
Sign-up for Amicus Therapeutics Advances Chaperone-Enzyme Replacement Therapy (ERT) Combination Platform in Pompe Disease investment picks
2013/5/9
12-Month Results From Ongoing Phase 3 Fabry Disease Monotherapy Study Anticipated 3Q13 CRANBURY, N.J., May 9, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) , a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced financial results for the first quarter ended March 31, 2013.
Sign-up for Amicus Therapeutics Announces First Quarter 2013 Financial Results and Corporate Updates investment picks
2013/3/12
CHART Programs Advancing in Lysosomal Storage Diseases CRANBURY, N.J., March 12, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) , a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced financial results for the full-year ended December 31, 2012.
Sign-up for Amicus Therapeutics Announces Full-Year 2012 Financial Results and Corporate Updates investment picks
2013/2/7
CRANBURY, N.J., Feb.
Sign-up for Amicus Therapeutics Announces Posters and Presentations at Lysosomal Disease Network WORLD Symposium investment picks
2013/3/4
CRANBURY, N.J., March 4, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) , today introduced Ch aperone- A dvanced R eplacement T herapy (CHART™) as the brand name for its technology platform that combines unique pharmacological chaperones with enzyme replacement therapy (ERT) for lysosomal storage diseases.
Sign-up for Amicus Therapeutics Introduces Proprietary "CHART" Platform Technology investment picks
2013/2/15
CRANBURY, N.J. and ORLANDO, Fla., Feb.
Sign-up for Amicus Therapeutics Presents Additional 6-Month Results from Phase 3 Fabry Monotherapy Study at LDN World Symposium investment picks
2013/2/13
CRANBURY, N.J. and ORLANDO, Fla., Feb.
Sign-up for Amicus Therapeutics Presents Additional Results From Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Study for Fabry Disease at LDN World Symposium investment picks
2013/5/2
CRANBURY, N.J., May 2, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Thursday, May 9, 2013 at 5:00 p.m. ET to discuss financial results for the first quarter ended March 31, 2013.
Sign-up for Amicus Therapeutics to Announce First Quarter 2013 Financial Results on May 9, 2013 investment picks
2013/3/7
CRANBURY, N.J., March 7, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Tuesday, March 12, 2013 at 5:00 p.m. ET to discuss financial results for the full-year ended December 31, 2012.
Sign-up for Amicus Therapeutics to Announce Full-Year 2012 Financial Results on March 12, 2013 investment picks
2013/2/4
CRANBURY, N.J., Feb.
Sign-up for Amicus Therapeutics to Participate in BIO CEO & Investor Conference and Leerink Swann Global Healthcare Conference investment picks
2013/4/24
CRANBURY, N.J., April 24, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F.
Sign-up for Amicus Therapeutics to Present at 12th Annual Needham Healthcare Conference investment picks
2013/2/27
CRANBURY, N.J., Feb.
Sign-up for Amicus Therapeutics to Present at Cowen and Company 33rd Annual Health Care Conference investment picks
2013/4/11
NEW YORK , April 11, 2013 /PRNewswire/ -- Amir Kassaei, Chief Creative Officer of DDB Worldwide, will lead the newly defined Integration Jury for LIA in 2013.
Sign-up for Amir Kassaei, CCO of DDB Worldwide, Returns To Chair the LIA Integration Jury investment picks
2013/4/30
Amira Nature Foods Ltd (the “Company” or “Amira;”) (NYSE: ANFI) , a leading global provider of packaged Indian specialty rice, today announced that it entered into a $48 million contract to supply third party branded basmati rice to a key repeat customer in the Europe, Middle East, and Africa (“EMEA”) region.
Sign-up for Amira Nature Foods Ltd Announces $48 Million Contract with a Repeat Customer investment picks
2013/2/25
Amira Nature Foods Ltd (the "Company") (NYSE: ANFI) , a leading global provider of packaged Indian specialty rice, today reported financial results for the third quarter and nine months ended December 31, 2012.
Sign-up for Amira Nature Foods Ltd Announces Third Quarter Fiscal Year 2013 Financial Results investment picks
2013/4/8
Amira Nature Foods Ltd (the “Company” or “Amira”) (NYSE: ANFI) , a leading global provider of packaged Indian specialty rice, today announced they were awarded BEST PARTNER in the “Staples” category for 2012 at the Bharti Walmart Private Limited Annual Supplier Conference.
Sign-up for Amira Nature Foods Ltd Awarded BEST PARTNER in the “Staples” Category from Bharti Walmart investment picks
2013/4/8
Amira Nature Foods Ltd (the “Company” or “Amira”) (NYSE: ANFI) , a leading global provider of packaged Indian specialty rice, today announced that despite the expiration of the lockup agreement between Amira and Karan A.
Sign-up for Amira Nature Foods Ltd Chairman and Chief Executive Officer Intends to Hold Shares Released from IPO Lockup investment picks
2013/4/4
Amira Nature Foods Ltd (the “Company” or “Amira”) (NYSE: ANFI) , a leading global provider of packaged Indian specialty rice, today announced that its subsidiary, Amira Pure Foods Private Limited, has entered into an agreement with a new South Korean customer to supply Indian medium short grain specialty rice for approximately $8.0 million, thereby making its first entry into the large South Korean market.
Sign-up for Amira Nature Foods Ltd Enters South Korean Market with New Customer Agreement to Supply Indian Specialty Rice investment picks
2013/2/7
Amira Nature Foods Ltd (the "Company") (NYSE: ANFI) , a leading global provider of packaged Indian specialty rice, will participate in Gulfood, the world’s largest annual food and hospitality show, on February 25-28, 2013 at the Dubai World Trade Centre in Dubai.
Sign-up for Amira Nature Foods Ltd to Participate in Gulfood 2013 investment picks
2013/2/21
Amira Nature Foods Ltd (the "Company") (NYSE: ANFI) , a leading global provider of packaged Indian specialty rice, today announced that Karan A.
Sign-up for Amira Nature Foods Ltd to Present at the Deutsche Bank Consumer, Retail, Gaming & Lodging Conference investment picks
2013/2/28
Amira Nature Foods Ltd (the "Company") (NYSE: ANFI) , a leading global provider of packaged Indian specialty rice, today announced that Karan A.
Sign-up for Amira Nature Foods Ltd to Present at the UBS Global Consumer Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Amgen to Pay $24.9 Million to Settle Kickbacks Allegations to Amira Nature Foods Ltd to Present at the UBS Global Consumer Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity